12 Best PathAI Alternatives & Competitors (2026)

Epic Systems supplies the dominant EHR platform with embedded analytics and scheduling modules. Its strength is deep clinical documentation and interoperability, yet it does not itself deliver AI-driven visit-capacity increases or operate care networks. Hospitals already on Epic may layer Scope AI-like tools on top rather than switch entirely when the priority is access expansion over record-keeping.

Teladoc Health operates a large virtual-care platform focused on on-demand video visits and chronic-care programs. Its strength lies in 24/7 access and employer contracts, yet it lacks Akido Labs emphasis on multiplying in-person slots or operating its own multi-site medical group. Pricing is typically subscription or per-visit through payers, making it cheaper for purely remote needs but less relevant when the goal is same-day house calls or zero-copay in-person expansion.

Oscar Health combines insurance with a tech layer for member navigation and virtual care. It offers transparent pricing and app-based experiences but remains payer-centric and does not run the provider-dense, AI-augmented in-person model Akido Labs uses to drive copay elimination and next-day access.

Philips integrates AI into patient monitoring and diagnostics with emphasis on connected care ecosystems. Its solutions often involve wearables or bedside devices for vital trends, differing from Tambua Health by lacking direct optical blood marker inference from consumer smartphones for enterprise companion programs.

Amwell provides white-label telehealth infrastructure used by health systems for video and scheduled visits. It excels at payer integrations and kiosk hardware but does not publish capacity-multiplier metrics comparable to Scope AI 10x in-person gains. Organizations seeking Akido-style house-call programs or street-medicine pilots usually find Amwell better suited for supplementing rather than replacing brick-and-mortar throughput.

PathAI provides AI-powered pathology analysis for cancer diagnostics with strong partnerships in pharma trials. It excels in image-based detection with extensive validation datasets. Compared to Biocogniv it focuses more narrowly on tissue slides rather than blood-based predictions and typically uses project-based pricing instead of broad lab subscriptions.

Insilico Medicine applies generative AI for drug discovery and biomarker identification. Its platform accelerates target discovery in aging and oncology. Unlike Biocogniv it serves pharmaceutical R&D teams rather than routine clinical labs with milestone-based rather than SaaS pricing.

One Medical runs membership-based primary-care clinics with app scheduling and 24/7 virtual options. Its modern clinics and employer contracts overlap with Akido Care locations, but it has not released AI capacity-multiplier claims or street-medicine research at the scale Akido Labs demonstrates.

Teladoc Health operates a large virtual-care platform focused on on-demand video visits and chronic-care programs. Its strength lies in 24/7 access and employer contracts, yet it lacks Akido Labs emphasis on multiplying in-person slots or operating its own multi-site medical group. Pricing is typically subscription or per-visit through payers, making it cheaper for purely remote needs but less relevant when the goal is same-day house calls or zero-copay in-person expansion.

LabCorp operates a vast network of physical laboratories offering comprehensive blood testing services with high regulatory clearance and insurance integration. It excels at precise confirmatory diagnostics across thousands of biomarkers but requires in-person draws, making it less ideal for frequent longitudinal monitoring in GLP-1 or liver programs compared to Tambua Health's smartphone-based optical inference. Pricing follows traditional fee-for-service models rather than enterprise AI subscriptions.

MDLive focuses on convenient virtual urgent care and behavioral health. Its low per-visit cost appeals for episodic needs, yet it has no equivalent to Akido Labs 96-location footprint or published research on AI-enabled street outreach, limiting its fit for systems prioritizing physical capacity growth.